...
首页> 外文期刊>ACS medicinal chemistry letters >Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics
【24h】

Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics

机译:融合类阿片激动剂-神经激肽1拮抗剂拟肽对急性和神经痛的双重缓解

获取原文
获取原文并翻译 | 示例
           

摘要

Herein, the synthesis and biological evaluation of dual opioid agonists-neurokinin 1 receptor (NK1R) antagonists is described. In these multitarget ligands, the two pharmacophores do not overlap, and this allowed maintaining high NK1R affinity and antagonist potency in compounds 12 and 13. Although the fusion of the two ligands resulted in slightly diminished opioid agonism at the mu- and delta-opioid receptors (MOR and DOR, respectively), as compared to the opioid parent peptide, balanced MOR/DOR activities were obtained. Compared to morphine, compounds 12 and 13 produced more potent antinociceptive effects in both acute (tail-flick) and neuropathic pain models (von Frey and cold plate). Similarly to morphine, analgesic tolerance developed after repetitive administration of these compounds. To our delight, compound 12 did not produce cross-tolerance with morphine and high antihyperalgesic and antiallodynic effects could be reinstated after chronic administration of each of the two compounds.
机译:在此,描述了双重阿片样激动剂-神经激肽1受体(NK1R)拮抗剂的合成和生物学评估。在这些多靶点配体中,这两个药效基团不重叠,因此可以在化合物12和13中保持较高的NK1R亲和力和拮抗力。 (分别为MOR和DOR),与阿片样物质母体肽相比,获得了平衡的MOR / DOR活性。与吗啡相比,化合物12和13在急性(甩尾)和神经性疼痛模型(冯·弗雷和冷板)中均产生更有效的镇痛作用。与吗啡相似,重复服用这些化合物后,其镇痛耐受性也随之提高。令我们高兴的是,化合物12与吗啡没有产生交叉耐受性,并且长期服用两种化合物后,可以恢复高的抗痛觉过敏和抗痛觉过敏作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号